Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? A systemic review

被引:14
作者
Yang, Mo [1 ]
Bhowmik, Debajyoti [1 ]
Wang, Xin [1 ]
Abughosh, Susan [1 ]
机构
[1] Univ Houston, Coll Pharm, Dept Clin Sci & Adm, Houston, TX 77030 USA
关键词
Systematic review; Combination pharmacological treatment; Smoking cessation intervention; Weight gain; SUSTAINED-RELEASE BUPROPION; RECEPTOR PARTIAL AGONIST; NICOTINE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; CIGARETTE-SMOKING; NALTREXONE AUGMENTATION; BODY-WEIGHT; EFFICACY; PLACEBO; PATCH;
D O I
10.1016/j.addbeh.2012.11.007
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Most smokers who quit smoking gain weight. There are some interventions designed to limit weight gain following smoking cessation. Objective: To conduct a systematic review to evaluate if combination pharmacological therapy interventions for smoking cessation are effective in reducing post-cessation weight gain. Methods: The following databases were researched: Medline, PubMed, PsycINFO, CENTRAL and EMBASE. Detailed inclusion and exclusion criteria were specified a priori before conducting abstract and full text screening. Included studies were required to: (1) report data on combination pharmacotherapy including at least one FDA-approved smoking cessation medication; (2) report outcome measure of weight change from baseline to the end of follow up; (3) incorporate a minimum of 2-week follow-up; (4) recruit adult smokers. Studies were excluded if they had (1) behavioral interventions; (2) sample size of <30; (3) switching medications; or (4) they were not written in English. Abstracts and the full texts were reviewed independently by two investigators. Inclusion of studies was decided by a third independent investigator in case of disagreement between the two primary investigators. Results: Out of 1873 studies identified, 1083 studies were included for abstract screening. Finally, 12 studies met the eligibility criteria after full text screening of 242 studies. Seven studies showed that participants in the combined therapy group had less post-cessation weight gain than those in the group of individual drugs or placebo. Four studies did not report differential weight gain measures by treatment groups. Only one study showed that post-treatment weight gain in the combined therapy group was more than the monotherapy group, although the result was not statistically significant. Conclusions: Seven out of twelve studies indicated that combination smoking cessation medications had less post-cessation weight gain than monotherapy or placebo in short term. Long term weight gain was not well documented by most of the studies and future research is warranted. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1865 / 1875
页数:11
相关论文
共 50 条
  • [31] The efficacy of exercise as an aid for smoking cessation in women -: A randomized controlled trial
    Marcus, BH
    Albrecht, AE
    King, TK
    Parisi, AF
    Pinto, BM
    Roberts, M
    Niaura, RS
    Abrams, DB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (11) : 1229 - 1234
  • [32] Are weight concerns predictive of smoking cessation? A prospective analysis
    Meyers, AW
    Klesges, RC
    Winders, SE
    Ward, KD
    Peterson, BA
    Eck, LH
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1997, 65 (03) : 448 - 452
  • [33] CESSATION FROM CIGARETTE-SMOKING - CHANGES IN BODY-WEIGHT, BODY-COMPOSITION, RESTING METABOLISM, AND ENERGY-CONSUMPTION
    MOFFATT, RJ
    OWENS, SG
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (05): : 465 - 470
  • [34] WEIGHT-GAIN AS A FUNCTION OF SMOKING CESSATION AND 2-MG NICOTINE GUM USE AMONG MIDDLE-AGED SMOKERS WITH MILD LUNG IMPAIRMENT IN THE 1ST 2 YEARS OF THE LUNG-HEALTH-STUDY
    NIDES, M
    RAND, C
    DOLCE, J
    MURRAY, R
    OHARA, P
    VOELKER, H
    CONNETT, J
    [J]. HEALTH PSYCHOLOGY, 1994, 13 (04) : 354 - 361
  • [35] Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist -: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up
    Nides, Mitchell
    Oncken, Cheryl
    Gonzales, David
    Rennard, Stephen
    Watsky, Eric J.
    Anziano, Rich
    Reeves, Karen R.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (15) : 1561 - 1568
  • [36] O'Hara P, 1998, AM J EPIDEMIOL, V148, P821, DOI 10.1093/oxfordjournals.aje.a009706
  • [37] A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation
    O'Malley, SS
    Cooney, JL
    Krishnan-Sarin, S
    Dubin, JA
    McKee, SA
    Cooney, NL
    Blakeslee, A
    Meandzija, B
    Romano-Dahlgard, D
    Wu, R
    Makuch, R
    Jatlow, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (06) : 667 - 674
  • [38] Impact of smoking cessation on bone mineral density in postmenopausal women
    Oncken, Cheryl
    Prestwood, Karen
    Kleppinger, Alison
    Wang, Yazhen
    Cooney, Judith
    Raisz, Lawrence
    [J]. JOURNAL OF WOMENS HEALTH, 2006, 15 (10) : 1141 - 1150
  • [39] Parsons A. C., 2009, COCHRANE DB SYST REV, V21
  • [40] Efficacy of bupropion alone and in combination with nicotine gum
    Piper, Megan E.
    Federman, E. Belle
    McCarthy, Danielle E.
    Bolt, Daniel M.
    Smith, Stevens S.
    Fiore, Michael C.
    Baker, Timothy B.
    [J]. NICOTINE & TOBACCO RESEARCH, 2007, 9 (09) : 947 - 954